Jennerex Biotherapeutics

Jennerex is a clinical-stage biotechnology company focused on developing and commercializing breakthrough oncolytic immunotherapies for patients with life-threatening cancers. The company’s lead candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, colorectal cancer, renal cell carcinoma, and ovarian cancer, while its next-generation candidate, JX-929, is being investigated for various other solid tumors. Jennerex is headquartered in San Francisco, with additional R&D operations in Ottawa, Canada, and South Korea.